AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Teva Pharmaceutical Industries Ltd.

Director's Dealing Dec 2, 2025

7082_rns_2025-12-01_98f6ac27-1104-4af7-9706-7aa68a4ec4cc.pdf

Director's Dealing

Open in Viewer

Opens in native device viewer

FORM 4 OMB APPROVAL
Check this box if no longer subject to Section 16.
Form 4 or Form 5 obligations may continue. See
Instruction 1(b).
Check this box to indicate that a transaction was
made pursuant to a contract, instruction or written
plan for the purchase or sale of equity securities of
the issuer that is intended to satisfy the affirmative
defense conditions of Rule 10b5-1(c). See
Instruction 10.
(Print or Type Responses)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
Estimated average burden hours per
1. Name and Address of Reporting Person *
Mignone Roberto
2. Issuer Name and Ticker or Trading Symbol
Teva Pharmaceutical Industries Limited [ TEVA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last)
(First)
C/O Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.,
(Middle) 3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025
X Director
Officer (give title below)
10% Owner
Other (specify below)

(Street)

(City) (State) (Zip)

Tel Aviv, L3 6944020

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

  1. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

1.Title of Security
(Instr. 3)
2. Transaction
Date (Month
/Day/Year)
2A. Deemed
Execution
Date, if any
(Month/Day
/Year)
3. Transaction
Code
(Instr. 8)
4. Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned
Following Reported Transaction(s)
(Instr. 3 and 4)
6.
Ownership
Form:
7. Nature
of Indirect
Beneficial
Code V Amount (A) or
(D)
Price Direct (D)
or Indirect
(I)
(Instr. 4)
Ownership
(Instr. 4)
Ordinary Shares (1) 11/26/2025 S 50,000 D \$ 26.0301 (2) 445,000 I [see
footnote]
(3)
Ordinary Shares (1) 105,315 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative
Security
(Instr. 3)
2. Conversion
or Exercise
Price of
Derivative
Security
3. Transaction
Date (Month
/Day/Year)
3A. Deemed
Execution
Date, if any
(Month/Day
/Year)
4. Transaction
Code
(Instr. 8)
5. Number of
Derivative Securities
Acquired (A) or
Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration
Date
(Month/Day/Year)
7. Title and Amount of
Underlying Securities
(Instr. 3 and 4)
8. Price of
Derivative
Security
(Instr. 5)
9. Number
of
Derivative
Securities
Beneficially
10.
Ownership
Form of
Derivative
Security:
11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or
Number of Shares
Owned
Following
Reported
Transaction
(s)
(Instr. 4)
Direct (D)
or Indirect
(I)
(Instr. 4)

Explanation of Responses:

  • 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.03 to \$26.035, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • 3. The 445,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.
/s/ Dov Bergwerk as attorney-in-fact for Roberto Mignone 12/01/2025
**
Signature of Reporting Person
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Talk to a Data Expert

Have a question? We'll get back to you promptly.